KRAS and colorectal carcinoma: Also, KRAS and BRAF mutations associated with abnormal glycolysis metabolism require the upregulation of GLUT1 expression [2], and CRC cells with aberrant SMAD4 expression are frequently associated with enhanced GLUT1 activity [24].